SU11248 for metastatic renal cell carcinoma (Stage IV) - horizon scanning review

Record ID 32005000229
Authors' objectives:

This study aims to assess the effectiveness of SU11248 for metastatic renal cell carcinoma (Stage IV).

Authors' recommendations: SU11248 is the first in a new class of oral tyrosine kinase inhibitors, which target both tumour replication and angiogenesis. It is currently in a phase III trials for first-line metastatic renal cell carcinoma (mRCC), and phase II registrational trials for second-line mRCC. As a first-line therapy SU11248 is being compared to interferon-alpha (INF-a) in 690 patients For second-line treatment SU11248 is in a single arm trial in 100 patients who have failed cytokine-based therapy (interferon-alpha and/or interleukin-2 (IL-2)). Interim results in 63 patients demonstrate a partial response rate of 33%, stabilisation (>3 months in 37% of patients, and median time to progression of 8.3 months.
Authors' methods: Overview
Project Status: Completed
Year Published: 2005
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England, United Kingdom
MeSH Terms
  • Antineoplastic Agents
  • Neoplasm Metastasis
  • Carcinoma, Renal Cell
Organisation Name: NIHR Horizon Scanning Centre
Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
Contact Email:
Copyright: National Horizon Scanning Centre (NHSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.